Hexarelin Research & Studies
Part of the full Hexarelin guide - a growth-hormone-releasing peptide reference compound, identity-verified with a COA on every vial.
In brief
The research framing for hexarelin in the source entry is organized around three receptor-pharmacology areas and is anchored to a single provided primary citation. Everything below is attributed only to the sources named in the entry; no additional studies, numbers, or claims are introduced.
The detail
A closer look
01
GHS-R1a agonist pharmacology (PLC/IP3/PKC/Ca signaling)
The first listed research area is GHS-R1a agonist pharmacology with the PLC / IP3 / PKC / calcium signaling readout. This is the cell-signaling-level investigation: characterizing how hexarelin's engagement of the ghrelin receptor propagates through the Gq/11 to phospholipase C branch and produces intracellular calcium mobilization and protein kinase C activation in pituitary somatotroph models. It is the laboratory question of which second-messenger systems the peptide recruits at its primary receptor.
02
Comparative GHRP receptor-binding studies
The second area is comparative growth-hormone-releasing-peptide receptor-binding work - studies that situate hexarelin alongside other GHRPs by receptor affinity and binding behavior. In this context the entry's structural notes matter: the D-2-methyl-tryptophan at position 2 and the D-phenylalanine at position 5 are described as shaping receptor affinity, which is precisely the kind of structure-to-binding relationship comparative GHRP studies examine. The 'key modification' fact (D-2-methyl-Trp at position 2, sourced to Cayman Chemical) supports this area.
03
CD36 scavenger-receptor binding in cardiovascular-tissue models
The third area is binding to the scavenger receptor CD36 in cardiovascular-tissue models. This is a separate-receptor line of inquiry, distinct from the pituitary GHS-R1a work, examining hexarelin as a CD36 ligand in ex-vivo cardiovascular tissue. The entry presents this strictly as receptor-binding characterization with no functional or therapeutic extension.
04
Primary citation and provenance
The single provided citation is Deghenghi, R., et al. (1994), 'GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats,' Life Sciences, PMID 7910650 - the originating report of hexarelin as a new GHRP, studied in a rodent (infant and adult rat) laboratory context. Physicochemical facts in the entry carry their own source hints: molecular weight is attributed to ChemicalBook / Cayman, the receptor designation (GHS-R1a plus CD36) to the GHRP literature, and the position-2 modification to Cayman Chemical. No DOI is provided for the citation, and no other studies are claimed.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. Hexarelin is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.